Jacob Johnson
Stock Analyst at Stephens & Co.
(3.62)
# 869
Out of 4,761 analysts
77
Total ratings
38.98%
Success rate
11.3%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $220.56 | +8.81% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $2.53 | +137.15% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $5.61 | +6.95% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $44.75 | +34.08% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $210.23 | +49.84% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $532.55 | +27.69% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $158.99 | +6.92% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $7.45 | -32.89% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $3.85 | +185.71% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $20.90 | +81.82% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $6.22 | +173.31% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.65 | +51.52% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $64.92 | +34.01% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $210.91 | +84.91% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $11.10 | +62.16% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.18 | +43.54% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $26.67 | +8.74% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $120.67 | +7.73% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $163.02 | +131.26% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $220.56
Upside: +8.81%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.53
Upside: +137.15%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $5.61
Upside: +6.95%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $44.75
Upside: +34.08%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $210.23
Upside: +49.84%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $532.55
Upside: +27.69%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $158.99
Upside: +6.92%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $7.45
Upside: -32.89%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $3.85
Upside: +185.71%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $20.90
Upside: +81.82%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $6.22
Upside: +173.31%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.65
Upside: +51.52%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $64.92
Upside: +34.01%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $210.91
Upside: +84.91%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $11.10
Upside: +62.16%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $4.18
Upside: +43.54%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $26.67
Upside: +8.74%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $120.67
Upside: +7.73%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $163.02
Upside: +131.26%